(Total Views: 415)
Posted On: 11/24/2019 5:46:12 PM
Post# of 148878
Hulk,
I hear you. The problem is that we are in OTC. Analysts have hundreds of opportunities out there perceived to be "safer".
The HIV market is very competitive and it is not easy to make a mark on it … unless one enters with disruptive technology.
Once FDA tells the world that they think this is just that (approving Leronlimab) they will start to look this way. Once we are up-listed then we will be off to the races.
Retail investors (and, to some extent, institutions) like us worry more about the continuous raises and the current financial situation of the company.
In Oncology we are still perceived as a "wild" shot. But, again, this will change with only one indication (human) where the science is validated.
We are almost there
GLTY
I hear you. The problem is that we are in OTC. Analysts have hundreds of opportunities out there perceived to be "safer".
The HIV market is very competitive and it is not easy to make a mark on it … unless one enters with disruptive technology.
Once FDA tells the world that they think this is just that (approving Leronlimab) they will start to look this way. Once we are up-listed then we will be off to the races.
Retail investors (and, to some extent, institutions) like us worry more about the continuous raises and the current financial situation of the company.
In Oncology we are still perceived as a "wild" shot. But, again, this will change with only one indication (human) where the science is validated.
We are almost there
GLTY
(0)
(0)Scroll down for more posts ▼
